The pharmaceutical community is excited by retatrutide, a novel dual GIP and GLP-1 target that’s showing remarkable results in early trials . This treatment works by imitating natural hormones to regulate appetite and promote feelings of satiety, ultimately contributing to noticeable fat decrease